Democritus University of Thrace (DUTH)
Διερεύνηση της κλινικής σημασίας μοριακών δεικτών που συμμετέχουν σε κομβικά μονοπάτια της καρκινογένεσης του μη-μικροκυτταρικoύ καρκίνου του πνεύμονα
Abstract
dc:descriptionPrognosis of patients with non-small cell lung cancer (NSCLC) remains dismal, with the exception of patients with early operable disease that exhibits the best rates of overall survival. In this subgroup of patients, there is urgent need for novel biomarkers with prognostic and/or predictive value. The main role of DNA repair is to correct the damages of DNA that are implicated in the process of carcinogenesis. Key molecule in this system is H2AX, and more specifically its phosphorylated type. The aim of our study was to examine the prognostic role of γ-Η2ΑΧ in patients with early operable NSCLC. We studied the immunohistochemical expression of γ-Η2ΑΧ as well as the expression levels of BRCA1 with RT-PCR, a molecule that is also implicated in the DNA repair system. We also studied the expression of p53, a classical key molecule in the regulation of apoptosis in combination with analysis of caspase 3 levels. Furthermore, we examined the genomic instability of our samples by analyzing the ploidy status with flow cytometry, Ki67 labeling index and EGFR mutations in the same cohort of 96 patients with early operable NSCLC. Our results showed that low expression levels of γ-Η2ΑΧ represent an independent factor of better overall survival in patients with early operable NSCLC. Patients with high expression levels of γ-Η2ΑΧ had a siginificantly worse overall survival (23.2 months vs 35.3 months of patients with low expression of γ-Η2ΑΧ, p=0.009). High expression levels of γ-Η2ΑΧ were significantly correlated with Τ3 tumors, advanced stage (ΙΙΙ/IV), lymphatic infiltration, aneuploidy and high expression levels of BRCA1. We also analyzed the combination of γ-Η2ΑΧ/p53 in order to define subgroups with different survival rates. The subgroup of patients with γ-Η2ΑΧ low/p53 low expression levels was associated with best survival rates as compared to the other expression profiles. Regarding BRCA1 expression analysis, our results were in keeping with the literature, showing that low BRCA1 expression levels were associated with a marginally siginificant better survival (p=0.08). An interesting finding of our results was that in the combined BRCA1/p53 analysis, BRCA1 expression was the determining factor of survival and not p53. In this context, patients with low expression of BRCA1 had a similar survival irrespective of p53 expression. We also found that BRCA1 and γ-Η2ΑΧ were significantly associated. No correlation between BRCA1 levels and EGFR mutations was detected. The use of multivariate cox proportional hazards regression analysis showed that independent factors for worse overall survival were: a) squamous carcinomas, b) N2 tumors, c) low grade tumors, d) tumors with high expression of p53 and e) tumors with high expression of γ-Η2ΑΧ. Regarding the progression free survival, patients with low expression of γ-Η2ΑΧ had an increased PFS as compared to patients with high γ-Η2ΑΧ (p=0,024). Similarly, patients with low expression of BRCA1 had also an increased PFS in comparison to patients with high expression of BRCA1 (p=0.021). Finally we analyzed our data with artificial neural networks (ANNs). ANNs outweighed logistic regression analysis in terms of accuracy. ANNs had a prediction success rate of about 88%. Although the success rate of correct prediction was not 100%, this study shows that the rate can be improved step by step when parameters and novel molecular parameters involved in lung cancer are added and considered together.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Matthaios, Dimitrios
- Ματθαίος, Δημήτριος
Subjects
dc:subject × 23- Μη-μικροκυτταρικός καρκίνος του πνεύμονος
- Μηχανισμοί επιδιόρθωσης DNA
- H2AX-ιστόνες
- Απόπτωση
- Πλοειδία
- Μεταλλάξεις του υποδοχέα του επιδερμικού αυξητικού παράγοντα
- Καρκινογένεση μη-μικροκυτταρικού καρκίνου πνεύμονα
- Non-small cell lung cancer
- DNA damage response
- H2AX-histones
- Apoptosis
- Ploidy
- BRCA1
- EGFR mutations
- Non-small cell lung cancer carcinogenesis
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Φυσικές Επιστήμες
- Βιολογία
- Medical and Health Sciences
- Clinical Medicine
- Natural Sciences
- Biological Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39097